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The chromogranin-A peptide catestatin modulates a wide range of processes, such as cardiovascular functions, innate immunity,
inflammation, and metabolism. We recently found that the cardiac antiadrenergic action of catestatin requires a PI3K-dependent
NO release from endothelial cells, although the receptor involved is yet to be identified. In the present work, based on the
cationic properties of catestatin, we tested the hypothesis of its interaction with membrane heparan sulphate proteoglycans,
resulting in the activation of a caveolae-dependent endocytosis. Experiments were performed on bovine aortic endothelial
cells. Endocytotic vesicles trafficking was quantified by confocal microscopy using a water-soluble membrane dye; catestatin
colocalization with heparan sulphate proteoglycans and caveolin 1 internalization were studied by fluorimetric measurements in
live cells. Modulation of the catestatin-dependent eNOS activation was assessed by immunofluorescence and immunoblot analysis.
Our results demonstrate that catestatin (5 nM) colocalizes with heparan sulphate proteoglycans and induces a remarkable increase
in the caveolae-dependent endocytosis and caveolin 1 internalization, which were significantly reduced by both heparinase and
wortmannin. Moreover, catestatin was unable to induce Ser1179 eNOS phosphorylation after pretreatments with heparinase and
methyl-𝛽-cyclodextrin. Taken together, these results highlight the obligatory role for proteoglycans and caveolae internalization in
the catestatin-dependent eNOS activation in endothelial cells.
1. Introduction
Chromogranin A (CgA) is a 48 kDa acidic glycoprotein [1–
3] and the main component of granins, a family of proteins
abundantly expressed in large dense core vesicles of neuroen-
docrine cells, neurons, and other secreting cells including
cardiac cells [4]. In the heart CgA is costored and cosecreted,
respectively, with catecholamines and natriuretic peptides
[4]. Catestatin (CST: hCgA
352−372
) is a 21 amino acid cationic
and hydrophobic peptide derived from the proteolytic cleav-
age of CgA. It was firstly discovered as an endogenous
allosteric nicotinic-cholinergic antagonist [5], but it is now
established as a multifunctional peptide modulating several
organs/systems, including the cardiovascular system [6, 7]. In
particular, it has been shown thatCST administration induces
vasodilation by multiple mechanisms. One mechanism relies
on the CST-dependent inhibition of catecholamine secretion,
through noncompetitive binding at the nicotinic cholinergic
receptor [5, 8]. Another potential mechanism for the CST-
induced vasodilation is through histamine release [9, 10],
which has been shown in vitro in mast cells mimicking
the receptor-independent peptidergic pathway proposed for
mastoparan and for other cationic and amphipathic peptides
[10]. Finally, CST has been shown to decrease sympathetic
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vascular tone by a direct excitatory effect on the GABAer-
gic inhibitory neurons of the caudal ventrolateral medulla
(CVLM), resulting in decreased sympathetic drive and a sub-
sequent fall in arterial pressure and heart rate [11]. Therefore,
CST plays crucial roles in the regulation and development of
hypertension. In humans, CST plasma levels are decreased
not only in hypertensive patients but also in their still-
normotensive offsprings [12]. However, plasma CST level has
recently been shown to be elevated in patients with heart
failure [13] or with coronary heart diseases [14].
Several studies indicate that exogenous CST rescues
hypertension [15] and improves baroreflex sensitivity [16] and
heart rate variability [17] in CgA knockout mice.
In addition to its important role in the control of blood
pressure, CST is now emerging as a peptide that has direct
cardiovascular actions under both basal and stimulated
conditions, suggesting that CST-induced negative inotro-
pism and lusitropism may be important components of its
hypotensive action [6, 18].
In particular in a previous study we showed a PI3K-
dependent nitric oxide (NO) release induced by CST in
endothelial cells [18], suggesting one of the intracellular
mechanisms underlying the cardiac antiadrenergic action of
this peptide.
Based on these findings, the aim of the present study was
to look into the initiating step required for this intracellular
cascade, as up to now, high affinity membrane receptors for
CST remain unknown. We therefore tested the hypothesis of
a receptor-independent cell membrane interaction.
This hypothesis was supported by several evidences: CST
adopts a 𝛽-sheet structure when interacting with negatively
charged membranes and may thus directly pass through cell
plasma membrane [19], and this property is believed to be
responsible for the antimicrobial activity against a wide array
of skin pathogens, including bacteria, yeast, and fungi [20,
21]. Moreover, in endothelial cells the CgA-derived peptide
vasostatin-1 (VS-1), bearing cationic and amphipathic prop-
erties, interacts with cell-surface proteoglycans and activates
eNOS phosphorylation on Ser1179 residue through a PI3K-
dependent endocytosis-coupled mechanism [22, 23]. The
above findings prompted us to test whether CST, by virtue of
its cationic and amphipathic properties, can work like VS-1.
2. Materials and Methods
2.1. Cell Culture, Solutions, and Drugs. Bovine Aortic
Endothelial (BAE-1) cells (European Collection of Cell
Cultures, Salisbury, Wiltshire, UK) were maintained in
Dulbecco’s Modified Eagle’s medium (DMEM, Sigma, St.
Louis, MO, USA) added with 10% heat-inactivated fetal calf
serum (FCS, Biowhittaker, Verviers, Belgium, lot 1SB0019),
100U/mL penicillin, 100 𝜇g/mL streptomycin, and 2mM
glutamine, at 37∘C, 5% CO
2
. Cells were used at passages 2–
6 and maintained in 1% FCS 24 h before the experiments.
M𝛽CD, H:ase, and Wm were purchased from Sigma.
Tyrode’s standard solution used for cell washes in colo-
calization experiments contained (mM) 154 NaCl, 4 KCl, 2
CaCl
2
, 1 MgCl
2
, 5.5 D-glucose, 5 Hepes, pH adjusted to 7.34
with NaOH.
CST was a kind gift by Professor Mahata and was
synthesized by the solid-phase method, using 9-fluorenylme-
thoxycarbonyl protection chemistry [24]. The concentration
of CST tested on BAE-1 cells was 5 nM, in the range of the
circulating levels of CgA (1.36 nM) found in healthy humans
[12].
Cy3-CST was purchased from Phoenix Pharmaceuticals.
2.2. Antibodies. The expressions of total eNOS and 𝛽-actin
were detected with monoclonal antibodies (Invitrogen and
BD Biosciences, resp.), while PSer1179eNOS and Caveolin 1
(Cav1) were evidenced with polyclonal antibodies that were
purchased, respectively, from Invitrogen and Sigma. heparan
sulphate was stained with a mouse monoclonal antibody
(MAB2040, Millipore) that we labeled with Alexa Fluor 488
using the APEX Antibody Labeling Kit (Invitrogen).
The secondary antibodies employed for immunofluores-
cence experiments were Alexa Fluor 488 anti-mouse (Molec-
ular Probes) for total eNOS and Cy3 anti-rabbit (Sigma) for
PSer1179eNOS and Cav1. For Western blot experiments we
used horseradish peroxidase-conjugated secondary antibod-
ies: anti-mouse for 𝛽-actin (Invitrogen) and anti-rabbit for
PSer1179eNOS (Amersham).
2.3. Immunofluorescence and Confocal Microscopy. Cells
grown on cover slides were fixed for 20 minutes in 4%
paraformaldehyde in 0.1M phosphate buffer (PB), pH 7.3.
After three washes with Dulbecco’s phosphate buffer saline
(PBS), cells were incubated 20 minutes with 0.3% Triton
and 1% bovine serum albumin (BSA, Sigma) in PBS and
stained with the primary antibody 24 h at 4∘C. Cover
slides were washed twice with PBS and incubated 1 h at
room temperature with the secondary antibody. After two
washes in PBS cover slides were mounted on standard
slides with DABCO (Sigma) and observed after 24 h under
confocal microscope. Fluorimetric measurements were also
performed with confocal microscopy, using an Olympus
Fluoview 200 laser scanning confocal system (Olympus
America Inc., Melville, NY, USA) mounted on an inverted
IX70 Olympus microscope, equipped with a 60X Uplan Fl
(NA 1.25) and a 100X Uplan Fl (NA 1.3) oil-immersion
objectives. Image processing and analysis were performed
with ImageJ software (Rasband, W.S., U.S. National Institutes
of Health, Bethesda, MA, http://rsb.info.nih.gov/ij/, 1997–
2013).
2.4. Western Blot Analysis. BAE-1 cells were lysed with lysis
buffer (100mMTris HCl, pH 8.0, 1mMMgCl
2
, plus inhibitor
cocktail) and incubated at −80∘C overnight. An equal volume
of sucrose buffer containing 20mM Tris Hepes pH 7.4 and
315mM sucrose plus inhibitor cocktail was added and cell
lysate was forced throughout a 25-gauge needle attached
on a 1mL syringe for several times. The inhibitor cocktail
contained 2 𝜇g/mL aprotinin, 0.1mM PMSF, 1mM sodium
orthovanadate, and 20mM sodium fluoride. Protein lysates
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(15 𝜇g of protein per lane) were run on 8% gradient SDS-
PAGE gel, transferred to a polyvinylidene fluoridemembrane
(PVDF; Millipore), and blocked overnight in TBST (10mM
Tris-HCl pH 7.5, 0.1M NaCl, and 0.1% Tween 20) plus 5%
nonfat dry milk (Biorad). PVDF was incubated, with gentle
agitation, 1 h at 30∘C with a polyclonal anti-PSer1179eNOS
antibody. Membranes were washed three times with TBST
andwere incubated 1 h at room temperature with horseradish
peroxidase-conjugated secondary antibodies before being
washed again three times with TBST. Protein band detection
was performed by chemiluminescence using the Super Signal
West Pico Kit (Pierce).
2.5. Endocytotic Vesicles Trafficking. Thewater-soluble mem-
brane dye N-(3-triethylaminopropyl)-4-(p-dibutylaminosty-
ryl) pyridinium dibromide (FM 1-43, Invitrogen) was used to
label plasmalemma-derived vesicles, as previously described
[25], and therefore to quantify endocytosis by confocal
microscopy. BAE-1 cells grown on glass-bottom dishes (Mat-
Tek Corporation) were incubated at 37∘C-5% CO
2
for 15min
in PBS containing 5 𝜇g/mL FM 1-43, for control condition
and in Hepes buffered saline solution (HBSS) plus 5 nM CST
for experimental condition. Before fixation for 20 minutes in
4% paraformaldehyde, cells were washed three times in ice-
cold dye-free PBS containing BSA (6mg/mL, fraction𝑉, 99%
pure, endotoxin free; Sigma) to remove all unincorporated
fluorescent probes from the external surface of endothelial
cells. To investigate the involvement of heparan sulphate
proteoglycans (HSPGs) in CST-dependent processes, we
pretreated BAE-1 cells with 2U/mL Heparinase III (H:ase)
from Flavobacterium heparinum (Sigma) for 3 h at 37∘C,
5% CO
2
. After two washes with PBS, cells were incubated
for 15min with PBS plus 5 nM CST and we proceeded as
described above. To investigate the role of PI3K pathway in
the formation of vesicles, we pretreated BAE-1 cells with the
PI3K inhibitor Wortmannin (Wm, 100 nM) for 20min and
then we added 5 nM CST. For each experiment we randomly
acquired three fields/sample. Endocytosis quantification was
performed with ImageJ software: briefly, after creating the 𝑧-
axis reconstruction (i.e., average of the slices) of the stack,
the quantity of intracellular stained vesicles was analyzed by
evaluating the fluorescence intensity/cell/field.
2.6. Colocalization Studies with CST and HSPGs. Mono-
clonal anti-heparin/heparan sulfate antibody (anti-HSPGs
MAB2040, Millipore) was conjugated with Alexa Fluor 488
using a commercial kit (APEX Antibody Labeling Kit, Invit-
rogen); briefly 10 𝜇L of Alexa Fluor-anti-HSPGs was freshly
prepared before the experiment. Fluorescent CST (Cy3-CST)
was purchased from Phoenix Pharmaceuticals. BAE-1 cells
grown on 35mm glass bottom dishes were treated at 4∘C
for 10min with Alexa Fluor-anti-HSPGs, followed by a rapid
(2min) exposure to Cy3-CST (5 nM), and after two washes
in Tyrode’s solution cells were rapidly transferred to the stage
of the confocal microscope. Single fields were captured (60x
objective) using separately 488 and 568 nm laser lines to
avoid bleed through and ensure specific fluorescence. Images
were analysed with the ImageJ/Fiji command “Colocalization
Threshold.”
2.7. Transfection with GFP-Cav1. Transfection of BAE-1 cells
was performed with the cationic liposome Lipofectamine
(Lipofectamine 2000TM, Life Technologies, Carlsbad, CA).
Endothelial cells were seeded into P-10 flasks (Costar, Cam-
bridge, MA) at 30% confluence and allowed to attach and
grow to reach 90% confluence; transfection was performed
using 1𝜇L of Lipofectamine 2000TM and 1𝜇g of GFP-Cav1
plasmid DNA in 120𝜇L of Opti-MEM (Life Technologies)
for 6 h at 37∘C, 5% CO
2
. Before observations, transfected
BAE-1 cells were incubated 24 h to allow protein expres-
sion. Confocal fluorimetric measurements were performed
as described in the “Immunofluorescence and Confocal
Microscopy” section.
2.8. Statistical Analysis. All values are presented as the
mean ± S.E.M. Statistical comparisons were performed with
ANOVA analysis followed by Bonferroni correction for post
hoc tests. Significance was accepted at a 𝑃 level < 0.05.
3. Results
3.1. CST Induces Endocytotic Vesicles Formation That Is Abol-
ished by Both Heparinase and Wortmannin. The role of CST
in the endocytotic process was evaluated by incubating BAE-
1 cells with the styryl pyridinium membrane probe FM 1-43
(5 𝜇g/mL), in order to visualize plasmalemma-derived endo-
cytotic vesicles.
To quantify these results we randomly acquired three
fields per sample in each experiment and then evaluated the
fluorescence intensity value/n∘ cell/field (see Section 2), in
control condition and after CST stimulation.
We observed that CST (5 nM) induced a significant
increase in the FM 1-43 fluorescence (Figure 1), indicating a
stimulation of the endocytotic process.
As the molecular properties of CST (little, amphipathic,
and cationic peptide) resemble those of the polycationic
peptides (cell penetrating peptides orCPPs), we hypothesized
that the first contact of this peptide with the cell surface takes
place through proteoglycans, as we previously demonstrated
for VS-1 [22]; internalization mechanisms mediated by
HSPGs interaction involving different routes of endocytosis
have indeed been described for several CPPs [26].
In order to verify thismechanism,HSPGswere selectively
removed from the cell surface by pretreatment of cells with
H:ase (2U/mL). After this step, CST strongly reduced its
ability to stimulate endocytosis (Figure 1), suggesting that
CST binding toHSPGs is fundamental to start its intracellular
cascade.
In a recent work we showed that in BAE-1 cells CST
induced a PI3K-dependent NO release [18]. To investigate
the role of PI3K pathway also in CST-dependent formation
of endocytotic vesicles, we performed FM 1-43 detection in
the presence of the PI3K inhibitor Wm (100 nM). As shown
in Figure 1, pretreatment withWm strongly reduced the CST-
activated endocytosis.
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Figure 1: CST stimulates a PI3K-proteoglycan dependent endocytotic machinery in BAE-1 cells. BAE-1 cells incubated with the water-soluble
styryl pyridinium membrane dye (FM 1-43). Pseudocolor images better show the fluorescence intensity increase correlated with the rise in
vesicles formation consequent to stimulation with CST 5 nM. In CST + H:ase and CST +Wm samples fluorescence intensity was comparable
to control levels. Surface plots close to each image display 3D graphs of pixels intensities in a pseudocolor image. The height and the color
represent the pixel intensity.
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Figure 2: Endocytosis quantification. To quantify the endocytotic process stimulated by CST 5 nM, we evaluated FM 1-43 fluorescence
intensity value/n∘ cell/field (see Section 2) in the different experimental conditions. The bar graph shows the variation of fluorescence
intensity/n∘ cell/field with respect to control. CST = 186.8 ± 60.36%; H:ase + CST = 30.36 ± 30.24%; Wm + CST = 31.09 ± 24.11%; 𝑛 = 7
endocytosis experiments (3 fields/sample, about 35 cells/fields); 𝑃 < 0.05.
The bar graph in Figure 2 summarizes this set of experi-
ments (percentage of fluorescence intensity/cell/field increase
above control: CST = 186.8 ± 60.36%; H:ase + CST = 30.36 ±
30.24%; Wm + CST = 31.09 ± 24.11%; 𝑛 = 7 endocytosis
experiments: 3 fields/sample, about 35 cells/fields; 𝑃 <
0.05).
3.2. CST Colocalizes with Heparan Sulphate Proteoglycans. To
prove the interaction between CST andHSPGswe performed
colocalization experiments in live cells by using Cy3-CST and
Alexa Fluor 488-anti-HSPGs.
In these experiments the fluorescent antibody against
heparan sulphate (1 : 200) was incubated 10min at 4∘C (to
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Figure 3: CST colocalizes with HSPGs. Representative confocal fluorescence images of BAE-1 cells incubated with both Alexa Fluor 488-
anti-HSPGs (green signal) and Cy3-CST (red signal), showing the high levels of colocalization for CST and HSPGs (% of colocalization =
73.4 ± 0.02%, 3 separate experiments, 6 fields/sample, about 25 cells/field).
avoid endocytosis) with BAE-1 cells cultured on glass bottom
dishes. The excess of antibody was removed by two washes
and then cells were incubated 2min at 4∘C with 5 nM Cy3-
CST. After two additional washes, cells were observed in
confocal microscopy.
The results from these experiments (Figure 3) reveal that
the colocalization between CST andHSPGs was very high (%
of colocalization = 73.4 ± 0.02%, 3 separate experiments, 6
fields/sample, about 25 cells/field).
3.3. CST Induces Caveolin-1 Mobilization. As CST stimulates
NOproduction [18] and several reports propose amechanism
of eNOS activation involving caveolae endocytosis [27, 28],
we hypothesized that the endocytotic process triggered by
CST was caveolae-dependent. To verify this hypothesis we
followed the cellular localization of Cav1 by transfecting
BAE-1 cells with GFP-Cav1. Cells were transfected with high
efficiency (up to 95%)withGFP-Cav1 plasmid (see Section 2).
In transfected live cells GFP-Cav1 signal was confined in
plasmamembranes, while in the presence of CST 5 nM green
fluorescence appeared clearly diffused in the cytosol, as a con-
sequence ofCav1 internalization, thus producing a substantial
increase of the overall fluorescent signal; pretreatment with
H:ase strongly reduced CST ability to stimulate this process
(Figures 4(a) and 4(b); percentage of fluorescence intensity
variation above control: CST = 86.94 ± 25.51%; H:ase + CST
= −0.07 ± 22.20%; 𝑛 = 3 sets of experiments, 3 fields/sample,
about 40 cells/fields; 𝑃 < 0.05).
In order to further analyze the internalization of GFP-
Cav1 in transfected BAE-1 cells, we evaluated GFP fluores-
cence values in specific regions localized in plasma mem-
brane and in cytosol during CST 5 nM administration.
We found (Figure 4(c)) that during CST treatment GFP-
Cav1 fluorescence intensity decreased in the plasma mem-
brane while being increased in the cytosol (percentage of
fluorescence intensity with respect to control: membrane=
−19.34 ± 1.22%; cytosol = 122.60 ± 3.49%; 𝑛 = 17 cells; 𝑃 <
0.05). These results confirm that CST administration induces
Cav1 displacement from plasma membrane; pretreatment
of BAE-1 transfected cells with H:ase reverts CST effect
(percentage of fluorescence intensity with respect to control:
membrane = 54.27± 9.37%; cytosol = −98.46± 0.09%; 𝑛 = 17
cells; 𝑃 < 0.05; data not shown).
3.4. CST Breaks Caveolin-1/eNOS Colocalization. As CST
stimulates endocytosis, induces Cav1 internalization, and, as
shown in our previous report, enhances NO production [18]
(Bassino et al., 2011), we hypothesized amechanism for eNOS
activation mediated by the displacement of the protein from
Cav1 binding. Dissociation of eNOS from Cav1 has been
indeed shown as a marker of eNOS activation [29].
To verify this hypothesis we followed cellular colocal-
ization of Cav1 and eNOS by immunofluorescence experi-
ments (Figure 5). We observed that CST strongly reduced
eNOS/Cav1 colocalization at plasma membrane detected in
control condition. Moreover, Wm was able to restore this
colocalization, confirming the role of PI3K in mediating CST
intracellular signaling.
To quantify colocalization results, Pearson correlation
coefficients were calculated for each experimental condition
(Figure 5(b); control = 0.84±0.09; CST = −0.07±0.05; Wm +
CST = 0.69 ± 0.18; 𝑛 = 8 sets of experiments, 3 fields/sample,
about 30 cells/fields; 𝑃 < 0.05).
3.5. Caveolae Disruption and HSPGs Removal Both Abolish
CST-Induced eNOS Phosphorylation. To strongly demon-
strate the proposed pathway of a CST-dependent caveolae
internalization and eNOS activation triggered by HSPGs,
we evaluated the level of CST-induced PSer1179eNOS after
both caveolae disruption by methyl-𝛽-cyclodextrin (MBCD,
5mM) and HSPGs removal (by H:ase, 3 h). Our results from
Western blot experiments (Figure 6) showed a significant
reduction of the CST-dependent eNOS phosphorylation in
both conditions (%PSer1179eNOS/𝛽-actin: control = 3.59 ± 1;
CST = 18.81 ± 1.57; M𝛽CD + CST = 3.48 ± 1.5, H:ase + CST
= 1.63 ± 0.41; 𝑛 = 3; 𝑃 < 0.05), confirming the obligatory
requirement of proteoglycans and caveolae integrity to allow
the CST-dependent intracellular pathway activation.
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(c)
Figure 4: CST induces proteoglycan-dependent Cav1 internalization in GFP-Cav1 transfected BAE-1 cells. (a) Representative time course of
the fluorescence intensity in single BAE-1 cells transfected with Cav-1-GFP and stimulated with H:ase + CST or with CST alone. Subpanels
1 and 2: confocal pseudocolor images of CST-treated BAE-1 cells from the correspondent time points indicated by the arrows, showing
membrane (1) and cytosolic (2) localizations of GFP-Cav1 after CST treatment. (b) Bar graphs representing the percent variation with respect
to control of the fluorescent GFP-Cav1 signal in the different experimental conditions (CST = 86.94± 25.51%; H:ase + CST = −0.07±22.20%;
𝑛 = 3 sets of experiments, 3 fields/sample, about 40 cells/fields; 𝑃 < 0.05). (c) Bar graph representing the percent variation with respect
to control of the fluorescent GFP-Cav1 signal during CST 5 nM treatment, respectively, in plasma membrane and in cytosol (membrane =
−19.34 ± 1.22%; cytosol = 122.6 ± 3.49%; 𝑛 = 17 cells; 𝑃 < 0.05).
4. Discussion
Our results show that in endothelial cells CST activates
eNOS through HSPGs and caveolae-dependent endocytotic
mechanism. The findings are consistent with our previous
results showing that proteoglycans/PI3K-dependent caveolae
endocytosis acts as the initiating factor for the intracellular
cascade activated in endothelial cells by VS-1, the major
N-terminal peptide derived from CgA [22, 23]. Our previ-
ous studies identifying a PI3K-dependent NO release from
endothelial cells as the intracellular mechanisms involved in
the cardiac antiadrenergic action of CST [18] prompted us to
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Figure 5: CST prevents Cav1/eNOS colocalization in a PI3K-dependent manner. (a) Confocal immunofluorescence images of BAE-1 cells
showing the typical membrane localization of Cav1 (red staining) and eNOS (green staining). After CST administration, Cav1 dissociated
from eNOS and staining diffused in the cytosol. This effect was reversed by Wm pretreatment. Immunofluorescence detection was carried
out using Alexa Fluor 488 anti-mouse for total eNOS and Cy3 anti-rabbit for Cav1. Scale bar: 20𝜇m. (b) Bar graph representing Pearson
correlation values relative to Cav1 and eNOS staining in each experimental condition (control = 0.84 ± 0.09; CST = −0.07 ± 0.05; Wm + CST
= 0.69 ± 0.18; 𝑛 = 8 sets of experiments, 3 fields/sample, about 30 cells/fields; 𝑃 < 0.05).
uncover the steps upstream the intracellular cascade activated
by CST in endothelial cells.
First, we found that CST stimulates endocytotic vesicles
formation (Figure 1), which corresponds with the biochem-
ical reports on CST, reporting that this peptide, like other
members of the CPPs family, exhibits membrane-interaction
properties because of both its amphipathic structure and
extended hydrophobic region. In particular, CD and NMR
data indicate that CST folds into a short helical conforma-
tion that interacts with membranes and causes considerable
disordering at the level of the phospholipid head groups.
Moreover, two of the five residues of the helical region of CST
are arginines, an amino acid that has been proposed to form
hydrogen bond interactions with phospholipids [19].
It is widely accepted that some CPPs can directly translo-
cate across the plasma membrane of cells. CPPs-mediated
toxicity, manifested as a general increase in plasma mem-
brane permeability, could reflect some of these observed
features [30]. In this context, the ability of CST to target
variousmicroorganisms such as bacteria, fungi, and parasites
[21] and also host cells such as neutrophils by a direct
interaction with plasma membranes [31] falls in this general
property of CPPs.
However, direct translocation has been observed only
at high concentrations of CPPs (>10 𝜇M), while lower
doses were shown to activate endocytotic mechanisms. For
instance, studies of leukaemia cells showed that still at 2 𝜇M
extracellular concentration R8-Alexa488 labeled vesicular
structures, which were shown to be endosomes and lyso-
somes. Upon raising the concentration to 10𝜇M, instead, the
peptide was seen to flood into cells giving, in most cases,
uniform labeling throughout the cytoplasm and nucleus [32].
In this perspective our results with CST 5 nM, higher than but
comparable to the circulating concentrations of CgA found
in healthy humans [12] (0.5–2 nM), are consistent with the
activation of a more restricted endocytotic pathway.
Furthermore, our experiments also show that CST-
activated endocytosis required the presence of HSPGs (Fig-
ures 1 and 2) on the surface of endothelial cells and that CST
colocalizes with HSPGs (Figure 3).The strong anionic charge
present in proteoglycans makes them favorable binding sites
for cationic polymers, lipids, and polypeptides, which are
used for drug and gene delivery [33, 34]. There are evidences
that negatively charged carbohydrates, like HSPGs, located
on the plasma membrane may serve as electrostatic traps
for the cationic CPPs [30]. Interestingly, the most prominent
glycosaminoglycans on the surface of endothelial cells are
precisely heparan sulphates and one of themajor protein core
families of HSPGs is themembrane-bound glypicans, that are
enriched in caveolae, where a series of molecules involved
with eNOS signalling are localized [35, 36]. Furthermore,
glypican-1 has been hypothesized to be the mechanosensor
for eNOS phosphorylation and activation in the shear stress-
induced response [37]. It could be speculated that the CST-
mediated membrane perturbation through HSPGs binding
and phospholipid interactions could resemble the acute
membrane perturbation involved in shear stress.
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Figure 6: Both proteoglycans and caveolae are required to
allow CST-dependent eNOS phosphorylation. (a) Typical West-
ern blot experiment showing that CST-induced PSer1179eNOS was
reduced by both M𝛽CD (5mM, 30min) and H:ase (2U/mL). (b)
PSer1179eNOS/𝛽-actin ratio of densitometric values from Western
blots (%PSer1179eNOS/𝛽-actin: control = 3.59±1; CST = 18.81±1.57;
M𝛽CD + CST = 3.48 ± 1.5, H:ase + CST = 1.63 ± 0.41; 𝑛 = 3;
𝑃 < 0.05).
This matter, together with our previous finding of CST-
dependent eNOS activation [18], led us to propose a CST-
induced mechanism of caveolae endocytosis and conse-
quent eNOS activation. These assumptions are supported by
our findings, from both Cav1 transfection and Cav1/eNOS
immunofluorescence and colocalization experiments. Previ-
ous reports have proposed a mechanism of eNOS activation
coupled with caveolae internalization [27, 28] and dissocia-
tion of eNOS fromCav1 has been shown as amarker of eNOS
activation [29, 36].
In addition, we found that PI3K activity was required
in both endocytosis and eNOS/Cav1 trafficking, thus repre-
senting the essential key for the CST-activated intracellular
signaling. In agreement with these results, it is well known
that PI3K/Akt mediated Ser1179 phosphorylation represents
a common pathway among the multiple regulatory mech-
anisms affecting eNOS activity [36] and PI3K is widely
reported to have an important role inmembrane budding and
fission in endothelial cells [38].
Finally with the last experiments (Figure 6) we confirmed
our proposed pathway showing that caveolae disruption
and HSPGs removal both abolished the CST-induced eNOS
phosphorylation (Figure 6).
5. Conclusion
Based on our previous data on the CgA derived peptide VS-
1 and the present findings, we hypothesize a novel signal
transduction pathway for endogenous cationic and amphi-
pathic peptides in endothelial cells: HSPGs interaction and
caveolae endocytosis, coupled with a PI3K-dependent eNOS
phosphorylation.
Moreover, giving the wide range of processes, such as
innate immunity, inflammatory and autoimmune reactions,
cardiovascular modulations, and several homeostatic regu-
lations [39–45] affected by CST, the understanding of its
physiological working represents a founding point for further
applications.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
The work was supported by National Institutes of Cardiovas-
cular Research (INRC); MIUR ex-60% (GA) and PRIN-2008
(MPG). Sushil K. Mahata is supported by a Veterans Affairs
Research Career Scientist award.
References
[1] K. B. Helle, A. Corti, M.-H. Metz-Boutigue, and B. Tota, “The
endocrine role for chromogranin A: a prohormone for peptides
with regulatory properties,”Cellular andMolecular Life Sciences,
vol. 64, no. 22, pp. 2863–2886, 2007.
[2] B. Tota, M. C. Cerra, and A. Gattuso, “Catecholamines, cardiac
natriuretic peptides and chromogranin A: evolution and phys-
iopathology of a “whip-brake” system of the endocrine heart,”
Journal of Experimental Biology, vol. 213, no. 18, pp. 3081–3103,
2010.
[3] A. Bartolomucci, R. Possenti, S. K. Mahata, R. Fischer-Colbrie,
Y. P. Loh, and S. R. J. Salton, “The extended granin family:
structure, function, and biomedical implications,” Endocrine
Reviews, vol. 32, no. 6, pp. 755–797, 2011.
[4] M. Pieroni, A. Corti, B. Tota et al., “Myocardial production of
chromogranin A in human heart: a new regulatory peptide of
cardiac function,” European Heart Journal, vol. 28, no. 9, pp.
1117–1127, 2007.
[5] S. K.Mahata, D. T.O’Connor,M.Mahata et al., “Novel autocrine
feedback control of catecholamine release: a discrete chromo-
granin A fragment is a noncompetitive nicotinic cholinergic
antagonist,” Journal of Clinical Investigation, vol. 100, no. 6, pp.
1623–1633, 1997.
[6] T. Angelone, A. M. Quintieri, B. K. Brar et al., “The anti-
hypertensive chromogranin A peptide catestatin acts as a
novel endocrine/paracrine modulator of cardiac inotropism
BioMed Research International 9
and lusitropism,” Endocrinology, vol. 149, no. 10, pp. 4780–4793,
2008.
[7] S. K. Mahata, M. Mahata, M. M. Fung, and D. T. O’Connor,
“Catestatin: a multifunctional peptide from chromogranin A,”
Regulatory Peptides, vol. 162, no. 1–3, pp. 33–43, 2010.
[8] S. K. Mahata, M. Mahata, R. J. Parmer, and D. T. O’Connor,
“Desensitization of catecholamine release: the novel cate-
cholamine release-inhibitory peptide catestatin (chromogranin
A344-364) acts at the receptor to prevent nicotinic cholinergic
tolerance,” The Journal of Biological Chemistry, vol. 274, no. 5,
pp. 2920–2928, 1999.
[9] B. P. Kennedy, S. K. Mahata, D. T. O’Connor, and M. G. Ziegler,
“Mechanism of cardiovascular actions of the chromogranin A
fragment catestatin in vivo,”Peptides, vol. 19, no. 7, pp. 1241–1248,
1998.
[10] P. Kru¨ger, S. K. Mahata, and K. B. Helle, “Catestatin (CgA344-
364) stimulates rat mast cell release of histamine in a manner
comparable to mastoparan and other cationic charged neu-
ropeptides,” Regulatory Peptides, vol. 114, no. 1, pp. 29–35, 2003.
[11] A. H. Gaede and P. M. Pilowsky, “Catestatin, a chromogranin
A-derived peptide, is sympathoinhibitory and attenuates sym-
pathetic barosensitivity and the chemoreflex in rat CVLM,”
American Journal of Physiology-Regulatory Integrative andCom-
parative Physiology, vol. 302, no. 3, pp. R365–R372, 2012.
[12] D. T. O’Connor,M. T. Kailasam, B. P. Kennedy,M. G. Ziegler, N.
Yanaihara, and R. J. Parmer, “Early decline in the catecholamine
release-inhibitory peptide catestatin in humans at genetic risk of
hypertension,” Journal of Hypertension, vol. 20, no. 7, pp. 1335–
1345, 2002.
[13] L. Liu, W. Ding, R. Li et al., “Plasma levels and diagnostic value
of catestatin in patients with heart failure,” Peptides, vol. 46, pp.
20–25, 2013.
[14] L. Liu, W. Ding, F. Zhao, L. Shi, Y. Pang, and C. Tang, “Plasma
levels and potential roles of catestatin in patients with coronary
heart disease,” Scandinavian Cardiovascular Journal, vol. 47, no.
4, pp. 217–224, 2013.
[15] N. R. Mahapatra, D. T. O’Connor, S. M. Vaingankar et al.,
“Hypertension from targeted ablation of chromogranin A
can be rescued by the human ortholog,” Journal of Clinical
Investigation, vol. 115, no. 7, pp. 1942–1952, 2005.
[16] J. R. Gayen, Y. Gu, D. T. O’Connor, and S. K. Mahata, “Global
disturbances in autonomic function yield cardiovascular insta-
bility and hypertension in the chromogranin A null mouse,”
Endocrinology, vol. 150, no. 11, pp. 5027–5035, 2009.
[17] N. B. Dev, J. R. Gayen, D. T. O’Connor, and S. K. Mahata,
“Chromogranin A and the autonomic system: decomposition
of heart rate variability and rescue by its catestatin fragment,”
Endocrinology, vol. 151, no. 6, pp. 2760–2768, 2010.
[18] E. Bassino, S. Fornero, M. P. Gallo et al., “A novel catestatin-
induced antiadrenergic mechanism triggered by the endothe-
lial PI3KeNOS pathway in the myocardium,” Cardiovascular
Research, vol. 91, no. 4, pp. 617–624, 2011.
[19] M. Sugawara, J. M. Resende, C. M. Moraes et al., “Membrane
structure and interactions of human catestatin by multidimen-
sional solution and solid-state NMR spectroscopy,”The FASEB
Journal, vol. 24, no. 6, pp. 1737–1746, 2010.
[20] K. A. Radek, B. Lopez-Garcia, M. Hupe et al., “The neu-
roendocrine peptide catestatin is a cutaneous antimicrobial
and induced in the skin after injury,” Journal of Investigative
Dermatology, vol. 128, no. 6, pp. 1525–1534, 2008.
[21] J. Briolat, S. D. Wu, S. K. Mahata et al., “New antimicrobial
activity for the catecholamine release-inhibitory peptide from
chromogranin A,” Cellular and Molecular Life Sciences, vol. 62,
no. 3, pp. 377–385, 2005.
[22] R. Ramella, O. Boero, G. Alloatti, T. Angelone, R. Levi, and
M. P. Gallo, “Vasostatin 1 activates eNOS in endothelial cells
through a proteoglycan-dependent mechanism,” Journal of
Cellular Biochemistry, vol. 110, no. 1, pp. 70–79, 2010.
[23] S. Fornero, E. Bassino, M. P. Gallo, R. Ramella, R. Levi, and G.
Alloatti, “Endothelium dependent cardiovascular effects of the
chromogranin a-derived peptides vasostatin-1 and catestatin,”
Current Medicinal Chemistry, vol. 19, no. 24, pp. 4059–4067,
2012.
[24] S. K. Mahata, M. Mahata, A. R. Wakade, and D. T. O’Connor,
“Primary structure and function of the catecholamine release
inhibitory peptide catestatin (chromogranin A344-364): iden-
tification of amino acid residues crucial for activity,”Molecular
Endocrinology, vol. 14, no. 10, pp. 1525–1535, 2000.
[25] W. D. Niles and A. B.Malik, “Endocytosis and exocytosis events
regulate vesicle traffic in endothelial cells,” Journal of Membrane
Biology, vol. 167, no. 1, pp. 85–101, 1999.
[26] M. C. Morris, S. Deshayes, F. Heitz, and G. Divita, “Cell-
penetrating peptides: frommolecular mechanisms to therapeu-
tics,” Biology of the Cell, vol. 100, no. 4, pp. 201–217, 2008.
[27] N. A. Maniatis, V. Brovkovych, S. E. Allen et al., “Novel mecha-
nism of endothelial nitric oxide synthase activation mediated
by caveolae internalization in endothelial cells,” Circulation
Research, vol. 99, no. 8, pp. 870–877, 2006.
[28] F. A. Sanchez, D. D. Kim, R. G. Dura´n, C. J. Meininger, and W.
N. Dura´n, “Internalization of eNOS via caveolae regulates PAF-
induced inflammatory hyperpermeability to macromolecules,”
The American Journal of Physiology: Heart and Circulatory
Physiology, vol. 295, no. 4, pp. H1642–H1648, 2008.
[29] R. D. Minshall, W. C. Sessa, R. V. Stan, R. G. W. Anderson,
and A. B. Malik, “Caveolin regulation of endothelial function,”
American Journal of Physiology-Lung Cellular and Molecular
Physiology, vol. 285, no. 6, pp. L1179–L1183, 2003.
[30] A. T. Jones and E. J. Sayers, “Cell entry of cell penetrating
peptides: tales of tails wagging dogs,” Journal of Controlled
Release, vol. 161, no. 2, pp. 582–591, 2012.
[31] D. Zhang, P. Shooshtarizadeh, B. Laventie et al., “Two chromo-
granin a-derived peptides induce calcium entry in human neu-
trophils by calmodulin-regulated calcium independent phos-
pholipase A2,” PLoS ONE, vol. 4, no. 2, Article ID e4501, 2009.
[32] M. M. Fretz, N. A. Penning, S. Al-Taei et al., “Temperature-,
concentration- and cholesterol-dependent translocation of L-
and D-octa-arginine across the plasma and nuclear membrane
of CD34+ leukaemia cells,” Biochemical Journal, vol. 403, no. 2,
pp. 335–342, 2007.
[33] D. L. Rabenstein, “Heparin and heparan sulfate: structure and
function,” Natural Product Reports, vol. 19, no. 3, pp. 312–331,
2002.
[34] M. Belting, “Heparan sulfate proteoglycan as a plasma mem-
brane carrier,” Trends in Biochemical Sciences, vol. 28, no. 3, pp.
145–151, 2003.
[35] J.M. Tarbell, “Shear stress and the endothelial transport barrier,”
Cardiovascular Research, vol. 87, no. 2, pp. 320–330, 2010.
[36] I. Fleming, “Molecular mechanisms underlying the activation
of eNOS,” Pflugers Archiv European Journal of Physiology, vol.
459, no. 6, pp. 793–806, 2010.
[37] S. V. Lopez-Quintero, R. Amaya, M. Pahakis, and J. M. Tarbell,
“The endothelial glycocalyx mediates shear-induced changes in
10 BioMed Research International
hydraulic conductivity,” The American Journal of Physiology—
Heart and Circulatory Physiology, vol. 296, no. 5, pp. H1451–
H1456, 2009.
[38] P. Mellor, L. A. Furber, J. N. K. Nyarko, and D. H. Anderson,
“Multiple roles for the p85𝛼 isoform in the regulation and func-
tion of PI3K signalling and receptor trafficking,” Biochemical
Journal, vol. 441, no. 1, pp. 23–37, 2012.
[39] R. Aslam, M. Atindehou, T. Lavaux, Y. Ha¨ıkel, F. Schneider, and
M.-H. Metz-Boutigue, “Chromogranin a-derived peptides are
involved in innate immunity,”CurrentMedicinal Chemistry, vol.
19, no. 24, pp. 4115–4123, 2012.
[40] G. Aung, F. Niyonsaba, H. Ushio et al., “Catestatin, a neu-
roendocrine antimicrobial peptide, induces human mast cell
migration, degranulation and production of cytokines and
chemokines,” Immunology, vol. 132, no. 4, pp. 527–539, 2011.
[41] K. B. Helle, “Regulatory peptides from chromogranin A and
secretogranin II: putative modulators of cells and tissues
involved in inflammatory conditions,” Regulatory Peptides, vol.
165, no. 1, pp. 45–51, 2010.
[42] K. B. Helle, “The chromogranin A-derived peptides vasostatin-
I and catestatin as regulatory peptides for cardiovascular func-
tions,” Cardiovascular Research, vol. 85, no. 1, pp. 9–16, 2010.
[43] K. B. Helle, “Chromogranins A and B and secretogranin II as
prohormones for regulatory peptides from the diffuse neuroen-
docrine system,” Results and Problems in Cell Differentiation,
vol. 50, pp. 21–44, 2010.
[44] N. R.Mahapatra, “Catestatin is a novel endogenous peptide that
regulates cardiac function and blood pressure,” Cardiovascular
Research, vol. 80, no. 3, pp. 330–338, 2008.
[45] G. K. Bandyopadhyay, C. U. Vu, S. Gentile et al., “Catestatin
(Chromogranin A
352−372
) and novel effects on mobilization of
fat from adipose tissue through regulation of adrenergic and
leptin signaling,” Journal of Biological Chemistry, vol. 287, no.
27, pp. 23141–23151, 2012.
Submit your manuscripts at
http://www.hindawi.com
Pain
Research and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Toxins
Journal of
Vaccines
Journal of
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Antibiotics
International Journal of
Toxicology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Stroke
Research and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Drug Delivery
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in 
Pharmacological 
Sciences
Tropical Medicine
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Medicinal Chemistry
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Addiction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Emergency Medicine 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Autoimmune 
Diseases
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Anesthesiology 
Research and Practice
Scientifica
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Pharmaceutics
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
